AbbVie (ABBV) Cost of Revenue (2012 - 2026)

AbbVie (ABBV) has 15 years of Cost of Revenue data on file, last reported at $4.2 billion in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $4.2 billion, up 5.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.4 billion (up 9.56% YoY), and the FY2025 annual result was $18.2 billion, up 7.69% from the prior year.
• Cost of Revenue fell to $4.2 billion in Q1 2026 per ABBV's latest filing, from $4.6 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.5 billion in Q3 2023 and troughed at $4.0 billion in Q1 2023.
• A 5-year average of $4.5 billion and a median of $4.2 billion in 2026 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue surged 36.79% in 2023, then sank 35.05% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $4.2 billion in 2022, then surged by 36.79% to $5.7 billion in 2023, then fell by 22.93% to $4.4 billion in 2024, then grew by 3.55% to $4.6 billion in 2025, then fell by 7.34% to $4.2 billion in 2026.
• Business Quant data shows ABBV's Cost of Revenue at $4.2 billion in Q1 2026, $4.6 billion in Q4 2025, and $5.3 billion in Q3 2025.